Archive topic · MM-MRD implementation and probabilistic event classification. These are distinct research questions; a classifier result does not establish a transferable clinical MRD limit.
Primary MM-MRD paper →CLINICAL FLOW CYTOMETRY INTELLIGENCE
CFCM Intelligence
Independent analysis of clinical flow cytometry, validation, technology, AI, data and the industry behind it.
Clinical FlowValidation & QCTechnologyAI & DataIndustry
MARKET INTELLIGENCE
Track the market. Keep the evidence in view.
Explore technology, reagents, companies and regulation through source-led records with explicit dates and evidence boundaries.
Explore Market Intelligence →Editorial archive
Previously published CFCM analysis and scientific intelligence.
Archive dates identify the original CFCM reports or editorial-development notes, not retrospective website publication. Reports dated 14 August–18 September 2026 were recovered from their dated originals. Earlier dates are retained from the existing archive; 4, 6 and 12 August are corroborated by original conversations. The dates 27 July, 2 August and 9 August remain unverified archival metadata. Topic records are not full scientific articles. Follow Read article for the expanded CFCM analysis, or the labelled primary source for evidence.
FULL ARTICLES · NOW AVAILABLE
27 AUG 2026 · CLINICAL FLOWThe Best CD38 Antibody Depends on the Therapy →25 AUG 2026 · MRDYour Treatment Can Break Your MRD Panel →19 AUG 2026 · AI & DATACan an LLM Choose the Right Flow Panel? →The 40-Colour Race May Be Ending →Synthetic Controls, Spectral MRD and Reproducibility →Clinical Flow AI Under the EU AI Act →Chinese Spectral Cytometry Arrives in Europe →Flow Cytometry as a Cell-Therapy Release Assay →
NEW FULL ARTICLES
23 AUG · VALIDATION & QCCan Spectral AML MRD Be Standardised Across Multiple Centres? →21 AUG · AI & DATADinoFlow: Is Flow Cytometry Getting a Foundation Model? →20 AUG · AI & DATADeep Learning for Mature B-Cell Neoplasms Reaches Clinical-Scale Data →14 AUG · TECHNOLOGYHas Clinical Spectral Flow Cytometry Finally Arrived? →
Recovered report archive · 6–18 September 2026
Dates below are the dates explicitly written in the original CFCM reports, not the date these summaries were published on the website. These are topic records, not endorsements of every claim in the source reports. Links to full articles identify content expanded and source-checked for CFCM; this does not imply independent scientific review.
18 SEP 2026 · MRD sensitivity, sample-efficient AI and reference controls
Topics recorded in the original report: MRD sensitivity requirements, FlowLOT, lung-test intellectual property and synthetic controls.
17 SEP 2026 · Sample preparation and the meaning of agreement
Topics recorded: myeloma sample preparation, COMIP, mast-cell interpretation and analytical bottlenecks.
16 SEP 2026 · Fluorescence metrology and difficult MRD phenotypes
Topics recorded: MESF/ERF, assay comparability, megakaryoblastic AML and cell-therapy QC.
15 SEP 2026 · Spectral workflows and clinical panel standardisation
Topics recorded: FACSDiscover A7, 27-colour B-ALL MRD and implementation of MM-MRD.
14 SEP 2026 · Software workflows, EQA and assay reproducibility
Topics recorded: CellStudio, external quality assessment, intellectual property and reagent development.
13 SEP 2026 · Clinical-context extraction and operator variation
Topics recorded: institutional LLM panel selection, operator variability and hybrid clinical AI.
12 SEP 2026 · Immunodeficiency and complementary immune panels
Topics recorded: functional immunophenotyping, complementary panels and cell-therapy monitoring.
11 SEP 2026 · Reusable representations and cytometry beyond haematology
Topics recorded: DinoFlow, sputum cytometry, industrial monitoring and assay benchmarking.
10 SEP 2026 · Clinical cytometry partnerships and cell manufacturing
Topics recorded: Sysmex–Cytek, spectral trial workflows, T-cell selection and manufacturing reagents.
9 SEP 2026 · AML biomarkers and cell-therapy monitoring
Topics recorded: CD84, automated cell-therapy QC, compartment-specific CAR-T monitoring and organoids.
8 SEP 2026 · CAR-T enumeration and clinical AI deployment
Topics recorded: CAR-T kinetics, multicentre AI, spectral validation and bacterial impedance cytometry.
7 SEP 2026 · Industrial cytometry and myeloma analysis
Topics recorded: dairy testing, marrow information, AI evaluation and spectral workflow limitations.
6 SEP 2026 · Flow QC within cell-therapy manufacturing
Topics recorded: manufacturing-integrated QC, bioassay automation, molecular assays and scientific meetings.
Expanded evidence-based articles
The 40-Colour Race May Be Ending →Synthetic Controls, Spectral MRD and Reproducibility →Clinical Flow AI Under the EU AI Act →Chinese Spectral Cytometry Arrives in Europe →Flow Cytometry as a Cell-Therapy Release Assay →Clinical Notes — practical lessons →Juan Manuel Ojeda — author and disclosure →ARCHIVE · 29 AUG–05 SEP 2026
Peer-reviewed methods · A defined 17-colour PBMC/co-culture workflow. This is not validation of every spectral panel or a clinical MRD assay.
Primary methods paper →Peer-reviewed methods · CaptureBody links anti-CD45 and anti-IgG to create cell-based reference controls. The 31 August 2026 journal publication supersedes the February preprint; suitability remains reagent- and workflow-dependent.
CaptureBody journal record →Peer-reviewed study · CD3-relativisation was evaluated with 482 samples from 381 healthy donors and 100 post-surgical ICU samples, using six cytometers at four laboratories. This tests data alignment; it does not replace instrument QC or prove universal clinical equivalence.
Primary multicentre study →CFCM technical analysis · Evaluate spreading and the resolution of the final marker combinations as well as spectral similarity. A similarity score alone is not a clinical acceptance criterion.
Spectral validation resource →Regulatory record · On 13 August 2026, the FDA granted accelerated approval to an iberdomide combination using MRD-negative complete response as the major efficacy outcome. This does not establish interchangeability of all MRD assays.
FDA approval and trial endpoint →Consensus / recommendations · Johansson and colleagues' ESCCA paper, published 28 August 2026, describes a risk-based approach to process variability. It is guidance, not a patient cohort establishing a universal uncertainty target.
ESCCA recommendations →Research projects · CORDIS describes NeutroFlow biomarker development and PRISM physics-aware unmixing research. Project objectives are not completed clinical-validation results or regulatory approval.
NeutroFlow project record →PRISM project record →ARCHIVE · SUMMER 2026
28 AUG 2026 · ANALYSIS · TECHNOLOGY
The 40-Colour Race May Be Ending
Read article →Very high-parameter panels are technically impressive, but clinical value increasingly depends on standardisation, reproducibility and interpretable workflow design.
27 AUG · PAPER INTO PRACTICE
The Best CD38 Antibody Depends on the Therapy
Read article →Anti-CD38 therapy changes the analytical problem: clone choice must be validated against treatment context.
26 AUG · ANALYSIS
Flow Cytometry as a Cell-Therapy Release Assay
Read article →Cell and gene therapy may be one of the clearest growth areas for high-value validated flow workflows.
25 AUG · PAPER INTO PRACTICE
Your Treatment Can Break Your MRD Panel
Read article →Therapy can alter antigen expression enough to invalidate assumptions built into an MRD panel.
24 AUG · MARKET WATCH
European Market Entry and B-ALL MRD Consensus
Technology, regulation, local support and clinical standardisation increasingly overlap.
23 AUG · VALIDATION & QC
Can Spectral AML MRD Be Standardised Across Multiple Centres?
Read article →The unit of validation is the full network, not the cytometer alone.
22 AUG · RADAR
Synthetic Controls, Spectral MRD and Reproducibility
Read article →Controls matter when they reduce variability across time, sites and instruments.
21 AUG · AI & DATA
DinoFlow: Is Flow Cytometry Getting a Foundation Model?
Read article →Reusable representation learning could change how cytometry AI is built and validated.
20 AUG · AI & DATA
Deep Learning for Mature B-Cell Neoplasms Reaches Clinical-Scale Data
Read article →The next question is not classification alone, but interpretability, monitoring and failure handling.
19 AUG · PAPER INTO PRACTICE
Can an LLM Choose the Right Flow Panel?
Read article →Clinical panel selection points toward hybrid AI: language models plus deterministic safety constraints.
18 AUG · BEYOND LEUKOCYTES
Spectral Flow Moves Beyond the Clinical Lab
Microplastics, water monitoring and industrial applications broaden cytometry’s addressable market.
17 AUG · REGULATORY
Clinical Flow AI Under the EU AI Act
Read article →Accuracy is only one part of clinical AI: intended use, risk, oversight and lifecycle evidence matter.
16 AUG · MARKET WATCH
Chinese Spectral Cytometry Arrives in Europe
Read article →Evidence quality, regulatory positioning and local support will determine adoption.
15 AUG · INDUSTRY
Waters, BD Biosciences and the Next Phase of Clinical Cytometry
Industry consolidation and spectral validation point to a changing competitive landscape.
14 AUG · RADAR
Has Clinical Spectral Flow Cytometry Finally Arrived?
Read article →MRD, spectral-plus-imaging and AI-assisted analysis are converging toward clinical use.
12 AUG · MARKET WATCH
The CFCM Kill Test: Validate Demand Before Building
No platform before pain; no product before repeated willingness to pay.
09 AUG · AI & DATA
The Evidence Layer for Regulated AI
For scientific AI, the scarce layer may be the evidence system around the model.
06 AUG · CFCM
An Independent Technical Voice for European Cytometry
CFCM becomes an evidence-based, vendor-neutral publication for laboratories and industry.
04 AUG · CFCM
Building CFCM as an Editorial and Data Platform
Every article should leave behind structured, reusable knowledge.
02 AUG · AI & DATA
Private AI and Governance for Regulated Scientific Workflows
Confidentiality, auditability and evidence control remain major blockers to laboratory AI.
27 JUL · MARKET INTELLIGENCE
The Flow Cytometry Intelligence Landscape
A specialist market layer can connect products, companies, evidence, hiring and European adoption.